SALT LAKE CITY--(BUSINESS WIRE)--Great Basin Scientific, Inc. (NASDAQ:GBSN, GBSNU), a molecular diagnostics company, announced today that Carlos B. González, Ph.D. has joined the Company’s management team as Vice President of Engineering. González brings more than 20 years of medical device engineering and research experience—including tenure at market leaders such as Abbott and Siemens—to the Utah-based company.
As Vice President of Engineering, González will be responsible for leading the development of the next major platform upgrade to Great Basin’s analyzer, which the Company envisions will offer higher testing throughput in a significantly smaller footprint with a much shortened time to result. These enhancements will more efficiently accommodate the Company’s growing menu of low-plex and multiplex diagnostic tests and improve workflow as well as offer expanded reporting at customer sites. The Company expects to deliver the enhanced analyzer in 2016.
“With significant progress made on our test menu and our successful execution against our business plan, Great Basin is now poised to tackle enhancements to our instrumentation that will add significant value for our customers,” said Great Basin co-founder and Chief Executive Officer Ryan Ashton. “Our upgraded platform will be designed to shrink the instrument size and deliver faster time-to-result while using the same test cartridges as our current instrument. Additionally, we plan to enhance our usability and workflow benefits with an outstanding Apple-like user interface and flexible, powerful back-end reporting functionality that connects to the hospital or lab information system. We’re excited to have Carlos on board to develop this and future system enhancements that can be seamlessly adopted by our customers and will continue to simplify diagnostic workflow.”
Prior to Great Basin, González served as R&D director of instrument development at Abbott Point of Care. Previous to his position with Abbott POC, he held positions in new technology development with Siemens Diagnostics, Abbott Pharmaceutical (now Abbvie), and Lawrence Livermore National Laboratories where he helped demonstrate real-time PCR on a chip with nL volumes. Dr. González received his Ph.D. in Electrical Engineering from the University of California at Davis.
“I watched Great Basin quickly set itself apart from others in the molecular diagnostics space in the way they address workflow and cost, two issues that have previously limited the adoption of molecular diagnostics,” said González. “I am thrilled to join the Great Basin team as I share their vision for revolutionizing the way labs test and report results to clinicians. I look forward to applying my diagnostics-systems experience to the technology foundation that Great Basin has already established to deliver even greater value for our customers.”
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com.
Forward-Looking Statements
This press release includes forward-looking statement regarding events, trends and business prospects, which may affect our future operating results and financial position. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization, including the platform upgrade to Great Basin’s analyzer mentioned herein; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.
